Prometic discontinues Phase II of PBI-4050 to treat cystic fibrosis related diabetes

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said it will discontinue a Phase II trial of PBI-4050 to treat cystic fibrosis related diabetes due to slow patient enrollment. The company said most CF patients were ineligible for the trial as they were participating in other trials.

The double-blind, placebo-controlled, Canadian Phase II trial was evaluating the safety of PBI-4050 in about 90 cystic fibrosis patients with abnormal glucose control. Secondary endpoints included change from baseline in glucose level, insulin secretion and HbA1C following oral glucose tolerance test, change from baseline in pulmonary function parameters and weight...